Skip to content

Research Ready linked cohort for Metabolic Conditions (GLP-1 agonists)

As a leader in population genomics, we are actively building diverse germline clinico-genomic cohorts by fully integrating with health systems to implement precision medicine programs in a wide range of therapeutic areas. Our industry-leading WES platform (Exome+®) combined with consented, OMOP-standardized EHR data provides life science partners unparalleled access to comprehensive, scaled, longitudinal data for precision medicine development.

Driving drug discovery and development for Metabolic conditions with clinico-genomics

Leveraging our geographically extensive network of health system partners across the US, Helix has built a rapidly growing clinico-genomic cohort of thousands of GLP-1 agonist treated patients:

Linked Exome sequencing plus full EHR records from an ethnically diverse patient population 

All of the lab measures included in the pivotal trials, such as HbA1c and blood glucose, matched with patient vitals and demographic information

Access to the Helix Research Network database in the form of yearly data licenses and/or translational research collaborations

Download to Learn More

Additional Resources

Press Releases

Helix Launches 23,000-Patient Clinico-Genomic Cohort for Autoimmune Diseases to Advance Drug Discovery and Development

Read More

Webinars

Building a Precision Medicine Enterprise Strategy

Read More

Press Releases

Helix Launches Clinico-Genomic Datasets for Cardiovascular, Metabolic, Immunology and Inflammation Disorders

Read More